1
|
Whetter JN, Śmiłowicz D, Boros E. Exploring Aqueous Coordination Chemistry of Highly Lewis Acidic Metals with Emerging Isotopes for Nuclear Medicine. Acc Chem Res 2024; 57:933-944. [PMID: 38501206 DOI: 10.1021/acs.accounts.3c00781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/20/2024]
Abstract
Nuclear medicine harnesses radioisotopes for the diagnosis and treatment of disease. While the isotopes 99mTc and 111In have enabled the clinical diagnosis of millions of patients over the past 3 decades, more recent clinical translation of numerous 68Ga/177Lu-based radiopharmaceuticals for diagnostic imaging and therapy underscores the clinical utility of metal-based radiopharmaceuticals in mainstream cancer treatment. In addition to such established radionuclides, advancements in radioisotope production have enabled the production of radionuclides with a broad range of half-lives and emission properties of interest for nuclear medicine. Chemical means to form kinetically inert, in vivo-compatible species that can be modified with disease-targeting vectors is imperative. This presents a challenge for radiosiotopes of elements where the aqueous chemistry is still underdeveloped and poorly understood. Here, we discuss our efforts to date in exploring the aqueous, radioactive coordination chemistry of highly Lewis acidic metal ions and how our discoveries apply to the diagnosis and treatment of cancer in preclinical models of disease. The scope of this Account includes approaches to aqueous coordination of to-date understudied highly Lewis acidic metal ions with radioisotopes of emerging interest and the modulation of well-understood coordination environments of radio-coordination complexes to induce metal-catalyzed reactivity for separation and pro-drug applications.First, we discuss the development of seven-coordinate, small-cavity macrocyclic chelator platform mpatcn/picaga as an exemplary case study, which forms robust complexes with 44Sc/47Sc isotopes. Due to the high chemical hardness and pronounced Lewis acidity of the Sc3+ ion, the displacement of ternary ligand H2O by 18/natF- can be achieved to form an inert Sc-18/natF bond. Corresponding coordination complex natSc-18F is in vivo compatible and forms a theranostic tetrad with corresponding 44Sc/47Sc, 177Lu complexes all exhibiting homologous biodistribution profiles. Another exceptionally hard, highly Lewis acidic ion with underdeveloped aqueous chemistry and emerging interest in nuclear medicine is 45Ti4+. To develop de novo approaches to the mononuclear chelation of this ion under aqueous conditions, we employed a fragment-based bidentate ligand screening approach which identified two leads. The screen successfully predicted the formation of [45Ti][Ti(TREN-CAM)], a Ti-triscatechol complex that exhibits remarkable in vivo stability. Furthermore, the fragment-based screen also identified approaches that enabled solid-phase separation of Ti4+ and Sc3+ of interest in streamlining the isotope production of 45Ti and accessing new ways to separate 44Ti/44Sc for the development of a long-lived generator system. In addition to establishing the inert chelation of Ti4+ and Sc3+, we introduce controlled, metal-induced reactivity of corresponding coordination complexes on macroscopic and radiotracer scales. Metal-mediated autolytic amide bond cleavage (MMAAC) enables the temperature-dependent release of high-molar-activity, ready-to-inject radiopharmaceuticals; cleavage is selectively triggered by coordinated trivalent Lewis acid nat/68Ga3+ or Sc3+. Following the scope of reactivity and mechanistic studies, we validated MMAAC for the synthesis of high-molar-activity radiopharmaceuticals to image molecular targets with low expression and metal-mediated prodrug hydrolysis in vivo.This Account summarizes how developing the aqueous coordination chemistry and tuning the chemical reactivity of metal ions with high Lewis acidity at the macroscopic and tracer scales directly apply to the radiopharmaceutical synthesis with clinical potential.
Collapse
Affiliation(s)
- Jennifer N Whetter
- Department of Chemistry, University of Wisconsin─Madison, 1101 University Avenue, Madison, Wisconsin 53706, United States
| | - Dariusz Śmiłowicz
- Department of Chemistry, University of Wisconsin─Madison, 1101 University Avenue, Madison, Wisconsin 53706, United States
| | - Eszter Boros
- Department of Chemistry, University of Wisconsin─Madison, 1101 University Avenue, Madison, Wisconsin 53706, United States
| |
Collapse
|
2
|
Carbo-Bague I, Saini S, Cingoranelli SJ, Davey PRWJ, Tosato M, Lapi SE, Ramogida CF. Evaluation of a novel hexadentate 1,2-hydroxypyridinone-based acyclic chelate, HOPO-O 6-C4, for 43Sc/ 47Sc, 68Ga, and 45Ti radiopharmaceuticals. Nucl Med Biol 2024; 128-129:108872. [PMID: 38262310 DOI: 10.1016/j.nucmedbio.2023.108872] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2023] [Revised: 12/11/2023] [Accepted: 12/19/2023] [Indexed: 01/25/2024]
Abstract
INTRODUCTION Chelators play a crucial role in the development of metal-based radiopharmaceuticals, and with the continued interest in 68Ga and increasing availability of new radiometals such as 43Sc/47Sc and 45Ti, there is a growing demand for tailored chelators that can form stable complexes with these metals. This work reports the synthesis and characterization of a hexadentate tris-1,2-hydroxypyridonone chelator HOPO-O6-C4 and its in vitro and in vivo evaluation with the above mentioned radiometals. METHODS To investigate the affinity of HOPO-O6-C4, macroscopic studies were performed with Sc3+, and Ga3+ followed by DFT structural optimization of the Sc3+, Ga3+ and Ti4+ complexes. Further tracer studies with 43Sc (and 47Sc), 45Ti, and 68Ga were performed to determine the potential for positron emission tomography (PET) imaging with these complexes. In vitro stability studies followed by in vivo imaging and biodistribution studies were performed to understand the kinetic stability of the resultant radiometal-complexes of HOPO-O6-C4. RESULTS Promising radiolabeling results with HOPO-O6-C4 were obtained with 43Sc, 47Sc, 45Ti, and 68Ga radionuclides; rapid radiolabeling was observed at 37 °C and pH 7 in under 30-min. Apparent molar activity measurements were performed for radiolabeling of HOPO-O6-C4 with 43Sc (4.9 ± 0.26 GBq/μmol), 47Sc (1.58 ± 0.01 GBq/μmol), 45Ti (11.5 ± 1.6 GBq/μmol) and 68Ga (5.74 ± 0.7 GBq/μmol), respectively. Preclinical in vivo imaging studies resulted in promising results with [68Ga]Ga-HOPO-O6-C4 indicating a rapid clearance through hepatic excretion route and no decomplexation whereas [43Sc]Sc-HOPO-O6-C4, [47Sc]Sc-HOPO-O6-C4 and [45Ti]Ti-HOPO-O6-C4 showed modest and significant evidence of decomplexation, respectively. CONCLUSIONS The tris-1,2-HOPO chelator HOPO-O6-C4 is a promising scaffold for elaboration into a 68Ga- based radiopharmaceutical.
Collapse
Affiliation(s)
- Imma Carbo-Bague
- Department of Chemistry, Simon Fraser University, 8888 University Dr, Burnaby, BC V5A 1S6, Canada; Life Sciences, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC V6T 2A3, Canada
| | - Shefali Saini
- Department of Radiology, University of Alabama at Birmingham, 1824 6th Ave South, Birmingham, AL 35294, USA
| | - Shelbie J Cingoranelli
- Department of Radiology, University of Alabama at Birmingham, 1824 6th Ave South, Birmingham, AL 35294, USA
| | - Patrick R W J Davey
- Department of Chemistry, Simon Fraser University, 8888 University Dr, Burnaby, BC V5A 1S6, Canada; Life Sciences, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC V6T 2A3, Canada
| | - Marianna Tosato
- Department of Chemistry, Simon Fraser University, 8888 University Dr, Burnaby, BC V5A 1S6, Canada; Life Sciences, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC V6T 2A3, Canada
| | - Suzanne E Lapi
- Department of Radiology, University of Alabama at Birmingham, 1824 6th Ave South, Birmingham, AL 35294, USA.
| | - Caterina F Ramogida
- Department of Chemistry, Simon Fraser University, 8888 University Dr, Burnaby, BC V5A 1S6, Canada; Life Sciences, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC V6T 2A3, Canada.
| |
Collapse
|
3
|
Phipps MD, Cingoranelli S, Bhupathiraju NVSDK, Younes A, Cao M, Sanders VA, Neary MC, Daveny MH, Cutler CS, Lopez GE, Saini S, Parker CC, Fernandez SR, Lewis JS, Lapi SE, Francesconi LC, Deri MA. Sc-HOPO: A Potential Construct for Use in Radioscandium-Based Radiopharmaceuticals. Inorg Chem 2023; 62:20567-20581. [PMID: 36724083 PMCID: PMC10390652 DOI: 10.1021/acs.inorgchem.2c03931] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Three isotopes of scandium─43Sc, 44Sc, and 47Sc─have attracted increasing attention as potential candidates for use in imaging and therapy, respectively, as well as for possible theranostic use as an elementally matched pair. Here, we present the octadentate chelator 3,4,3-(LI-1,2-HOPO) (or HOPO), an effective chelator for hard cations, as a potential ligand for use in radioscandium constructs with simple radiolabeling under mild conditions. HOPO forms a 1:1 Sc-HOPO complex that was fully characterized, both experimentally and theoretically. [47Sc]Sc-HOPO exhibited good stability in chemical and biological challenges over 7 days. In healthy mice, [43,47Sc]Sc-HOPO cleared the body rapidly with no signs of demetalation. HOPO is a strong candidate for use in radioscandium-based radiopharmaceuticals.
Collapse
Affiliation(s)
- Michael D Phipps
- Ph.D. Program in Chemistry, The Graduate Center of the City University of New York, New York, NY 10016
- Department of Chemistry, City University of New York Hunter College, 695 Park Avenue, New York, New York 10065
- Department of Chemistry, Lehman College of the City University of New York, Bronx, NY 10468
- Medical Isotope Research & Production Laboratory, Collider-Accelerator Division, Brookhaven National Laboratory, Upton, NY, 11973, USA
| | - Shelbie Cingoranelli
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294
| | | | - Ali Younes
- Department of Chemistry, City University of New York Hunter College, 695 Park Avenue, New York, New York 10065
| | - Minhua Cao
- Department of Chemistry, City University of New York Hunter College, 695 Park Avenue, New York, New York 10065
| | - Vanessa A. Sanders
- Medical Isotope Research & Production Laboratory, Collider-Accelerator Division, Brookhaven National Laboratory, Upton, NY, 11973, USA
| | - Michelle C. Neary
- Department of Chemistry, City University of New York Hunter College, 695 Park Avenue, New York, New York 10065
| | - Matthew H. Daveny
- Department of Chemistry, City University of New York Hunter College, 695 Park Avenue, New York, New York 10065
| | - Cathy S. Cutler
- Medical Isotope Research & Production Laboratory, Collider-Accelerator Division, Brookhaven National Laboratory, Upton, NY, 11973, USA
| | - Gustavo E. Lopez
- Ph.D. Program in Chemistry, The Graduate Center of the City University of New York, New York, NY 10016
- Department of Chemistry, Lehman College of the City University of New York, Bronx, NY 10468
| | - Shefali Saini
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294
| | - Candace C. Parker
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294
| | - Solana R. Fernandez
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294
| | - Jason S. Lewis
- Program in Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY 10065
| | - Suzanne E. Lapi
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294
| | - Lynn C. Francesconi
- Ph.D. Program in Chemistry, The Graduate Center of the City University of New York, New York, NY 10016
- Department of Chemistry, City University of New York Hunter College, 695 Park Avenue, New York, New York 10065
| | - Melissa A. Deri
- Ph.D. Program in Chemistry, The Graduate Center of the City University of New York, New York, NY 10016
- Department of Chemistry, Lehman College of the City University of New York, Bronx, NY 10468
| |
Collapse
|
4
|
Marlin A, Koller A, Madarasi E, Cordier M, Esteban-Gómez D, Platas-Iglesias C, Tircsó G, Boros E, Patinec V, Tripier R. H 3nota Derivatives Possessing Picolyl and Picolinate Pendants for Ga 3+ Coordination and 67Ga 3+ Radiolabeling. Inorg Chem 2023; 62:20634-20645. [PMID: 37552617 DOI: 10.1021/acs.inorgchem.3c01417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/10/2023]
Abstract
We synthesized, thanks to the regiospecific N-functionalization using an orthoamide intermediate, two 1,4,7-triazacyclononane derivatives containing an acetate arm and either a methylpyridine or a picolinic acid group, respectively, Hnoapy and H2noapa, as new Ga3+ chelators for potential use in nuclear medicine. The corresponding Ga3+ complexes were synthesized and structurally characterized in solution by 1H and 13C NMR. The [Ga(noapy)]2+ complex appears to exist in solution as two diasteroisomeric pairs of enantiomers, as confirmed by density functional theory (DFT) calculations, while for [Ga(noapa)]+, a single species is present in solution. Solid-state investigations were possible for the [Ga(noapa)]+ complex, which crystallized from water as a pair of enantiomers. The average length of the N-Ga bonds of 2.090 Å is identical with that found for the [Ga(nota)] complex, showing that the presence of the picolinate arm does not hinder the coordination of the ligand to the metal ion. Protonation constants of noapy- and noapa2- were determined by potentiometric titrations, providing an overall basicity ∑log KiH (i = 1-4) that increases in the order noapy- < noapa2- < nota3- with increases in the negative charge of the ligand. Stability constants determined by pH-potentiometric titrations supplemented with 71Ga NMR data show that the stabilities of [Ga(noapy)]2+ and [Ga(noapa)]+ are lower compared to that of [Ga(nota)] but higher than those of other standards such as [Ga(aazta)]-. 67Ga radiolabeling studies were performed in order to demonstrate the potential of these chelators for 67/68Ga-based radiopharmaceuticals. The labelings of Hnoapy and H2noapa were nearly identical, outperforming H3nota. Stability studies were conducted in phosphate-buffered saline and in the presence of human serum transferrin, revealing no significant decomplexation of [67Ga][Ga(noapy)]2+ and [67Ga][Ga(noapa)]+ compared to [67Ga][Ga(nota)]. Finally, all complexes were found to be highly hydrophilic, with calculated log D7.4 values of -3.42 ± 0.05, -3.34 ± 0.04, and -3.00 ± 0.23 for Hnoapy, H2noapa, and H3nota, respectively, correlating with the charge of each complex and the electrostatic potentials obtained with DFT.
Collapse
Affiliation(s)
- Axia Marlin
- CEMCA, Université Brest, UMR 6521, CNRS, 6 avenue Victor le Gorgeu, 29238 Brest, France
- Department of Chemistry, Stony Brook University, 100 Nicolls Road, Stony Brook, New York 11794, United States
| | - Angus Koller
- Department of Chemistry, Stony Brook University, 100 Nicolls Road, Stony Brook, New York 11794, United States
| | - Enikö Madarasi
- Department of Physical Chemistry, Faculty of Science and Technology, University of Debrecen, Egyetem tér 1, H-4032 Debrecen, Hungary
- Doctoral School of Chemistry at the University of Debrecen, Egyetem tér 1, H-4032 Debrecen, Hungary
| | - Marie Cordier
- Institut des Sciences Chimiques de Rennes, Université Rennes, UMR 6226, CNRS, F-35000 Rennes, France
| | - David Esteban-Gómez
- Centro de Investigacións Científicas Avanzadas and Departamento de Química, Universidade da Coruña, Campus da Zapateira, rúa da Fraga 10, 15008A Coruña, Spain
| | - Carlos Platas-Iglesias
- Centro de Investigacións Científicas Avanzadas and Departamento de Química, Universidade da Coruña, Campus da Zapateira, rúa da Fraga 10, 15008A Coruña, Spain
| | - Gyula Tircsó
- Department of Physical Chemistry, Faculty of Science and Technology, University of Debrecen, Egyetem tér 1, H-4032 Debrecen, Hungary
| | - Eszter Boros
- Department of Chemistry, Stony Brook University, 100 Nicolls Road, Stony Brook, New York 11794, United States
| | - Véronique Patinec
- CEMCA, Université Brest, UMR 6521, CNRS, 6 avenue Victor le Gorgeu, 29238 Brest, France
| | - Raphaël Tripier
- CEMCA, Université Brest, UMR 6521, CNRS, 6 avenue Victor le Gorgeu, 29238 Brest, France
| |
Collapse
|
5
|
Woods JJ, Cosby AG, Wacker JN, Aguirre Quintana LM, Peterson A, Minasian SG, Abergel RJ. Macrocyclic 1,2-Hydroxypyridinone-Based Chelators as Potential Ligands for Thorium-227 and Zirconium-89 Radiopharmaceuticals. Inorg Chem 2023; 62:20721-20732. [PMID: 37590371 DOI: 10.1021/acs.inorgchem.3c02164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/19/2023]
Abstract
Thorium-227 (227Th) is an α-emitting radionuclide that has shown preclinical and clinical promise for use in targeted α-therapy (TAT), a type of molecular radiopharmaceutical treatment that harnesses high energy α particles to eradicate cancerous lesions. Despite these initial successes, there still exists a need for bifunctional chelators that can stably bind thorium in vivo. Toward this goal, we have prepared two macrocyclic chelators bearing 1,2-hydroxypyridinone groups. Both chelators can be synthesized in less than six steps from readily available starting materials, which is an advantage over currently available platforms. The complex formation constants (log βmlh) of these ligands with Zr4+ and Th4+, measured by spectrophotometric titrations, are greater than 34 for both chelators, indicating the formation of exceedingly stable complexes. Radiolabeling studies were performed to show that these ligands can bind [227Th]Th4+ at concentrations as low as 10-6 M, and serum stability experiments demonstrate the high kinetic stability of the formed complexes under biological conditions. Identical experiments with zirconium-89 (89Zr), a positron-emitting radioisotope used for positron emission tomography (PET) imaging, demonstrate that these chelators can also effectively bind Zr4+ with high thermodynamic and kinetic stability. Collectively, the data reported herein highlight the suitability of these ligands for use in 89Zr/227Th paired radioimmunotheranostics.
Collapse
Affiliation(s)
- Joshua J Woods
- Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States
| | - Alexia G Cosby
- Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States
| | - Jennifer N Wacker
- Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States
| | - Luis M Aguirre Quintana
- Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States
| | - Appie Peterson
- Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States
| | - Stefan G Minasian
- Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States
| | - Rebecca J Abergel
- Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States
- Nuclear Engineering, University of California Berkeley, Berkeley, California 94720, United States
| |
Collapse
|
6
|
Nguyen AT, Kim HK. Recent Developments in PET and SPECT Radiotracers as Radiopharmaceuticals for Hypoxia Tumors. Pharmaceutics 2023; 15:1840. [PMID: 37514026 PMCID: PMC10385036 DOI: 10.3390/pharmaceutics15071840] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2023] [Revised: 06/21/2023] [Accepted: 06/26/2023] [Indexed: 07/30/2023] Open
Abstract
Hypoxia, a deficiency in the levels of oxygen, is a common feature of most solid tumors and induces many characteristics of cancer. Hypoxia is associated with metastases and strong resistance to radio- and chemotherapy, and can decrease the accuracy of cancer prognosis. Non-invasive imaging methods such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) using hypoxia-targeting radiopharmaceuticals have been used for the detection and therapy of tumor hypoxia. Nitroimidazoles are bioreducible moieties that can be selectively reduced under hypoxic conditions covalently bind to intracellular macromolecules, and are trapped within hypoxic cells and tissues. Recently, there has been a strong motivation to develop PET and SPECT radiotracers as radiopharmaceuticals containing nitroimidazole moieties for the visualization and treatment of hypoxic tumors. In this review, we summarize the development of some novel PET and SPECT radiotracers as radiopharmaceuticals containing nitroimidazoles, as well as their physicochemical properties, in vitro cellular uptake values, in vivo biodistribution, and PET/SPECT imaging results.
Collapse
Affiliation(s)
- Anh Thu Nguyen
- Department of Nuclear Medicine, Jeonbuk National University Medical School and Hospital, Jeonju 54907, Republic of Korea
- Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju 54907, Republic of Korea
| | - Hee-Kwon Kim
- Department of Nuclear Medicine, Jeonbuk National University Medical School and Hospital, Jeonju 54907, Republic of Korea
- Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju 54907, Republic of Korea
| |
Collapse
|
7
|
Becker KV, Aluicio-Sarduy E, Bradshaw T, Hurley SA, Olson AP, Barrett KE, Batterton J, Ellison PA, Barnhart TE, Pirasteh A, Engle JW. Cyclotron production of 43Sc and 44gSc from enriched 42CaO, 43CaO, and 44CaO targets. Front Chem 2023; 11:1167783. [PMID: 37179772 PMCID: PMC10169720 DOI: 10.3389/fchem.2023.1167783] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2023] [Accepted: 04/18/2023] [Indexed: 05/15/2023] Open
Abstract
Introduction: 43Sc and 44gSc are both positron-emitting radioisotopes of scandium with suitable half-lives and favorable positron energies for clinical positron emission tomography (PET) imaging. Irradiation of isotopically enriched calcium targets has higher cross sections compared to titanium targets and higher radionuclidic purity and cross sections than natural calcium targets for reaction routes possible on small cyclotrons capable of accelerating protons and deuterons. Methods: In this work, we investigate the following production routes via proton and deuteron bombardment on CaCO3 and CaO target materials: 42Ca(d,n)43Sc, 43Ca(p,n)43Sc, 43Ca(d,n)44gSc, 44Ca(p,n)44gSc, and 44Ca(p,2n)43Sc. Radiochemical isolation of the produced radioscandium was performed with extraction chromatography using branched DGA resin and apparent molar activity was measured with the chelator DOTA. The imaging performance of 43Sc and 44gSc was compared with 18F, 68Ga, and 64Cu on two clinical PET/CT scanners. Discussion: The results of this work demonstrate that proton and deuteron bombardment of isotopically enriched CaO targets produce high yield and high radionuclidic purity 43Sc and 44gSc. Laboratory capabilities, circumstances, and budgets are likely to dictate which reaction route and radioisotope of scandium is chosen.
Collapse
Affiliation(s)
- Kaelyn V. Becker
- Department of Medical Physics, University of Wisconsin, Madison, WI, United States
| | | | - Tyler Bradshaw
- Department of Radiology, University of Wisconsin, Madison, WI, United States
| | - Samuel A. Hurley
- Department of Radiology, University of Wisconsin, Madison, WI, United States
| | - Aeli P. Olson
- Department of Medical Physics, University of Wisconsin, Madison, WI, United States
| | - Kendall E. Barrett
- Department of Medical Physics, University of Wisconsin, Madison, WI, United States
| | - Jeanine Batterton
- Department of Radiology, University of Wisconsin, Madison, WI, United States
| | - Paul A. Ellison
- Department of Medical Physics, University of Wisconsin, Madison, WI, United States
| | - Todd E. Barnhart
- Department of Medical Physics, University of Wisconsin, Madison, WI, United States
| | - Ali Pirasteh
- Department of Radiology, University of Wisconsin, Madison, WI, United States
| | - Jonathan W. Engle
- Department of Medical Physics, University of Wisconsin, Madison, WI, United States
- Department of Radiology, University of Wisconsin, Madison, WI, United States
| |
Collapse
|
8
|
Benabdallah N, Zhang H, Unnerstall R, Fears A, Summer L, Fassbender M, Rodgers BE, Abou D, Radchenko V, Thorek DLJ. Engineering a modular 44Ti/ 44Sc generator: eluate evaluation in preclinical models and estimation of human radiation dosimetry. EJNMMI Res 2023; 13:17. [PMID: 36853422 PMCID: PMC9975127 DOI: 10.1186/s13550-023-00968-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2022] [Accepted: 02/19/2023] [Indexed: 03/01/2023] Open
Abstract
BACKGROUND 44Sc/47Sc is an attractive theranostic pair for targeted in vivo positron emission tomographic (PET) imaging and beta-particle treatment of cancer. The 44Ti/44Sc generator allows daily onsite production of this diagnostic isotope, which may provide an attractive alternative for PET facilities that lack in-house irradiation capabilities. Early animal and patient studies have demonstrated the utility of 44Sc. In our current study, we built and evaluated a novel clinical-scale 44Ti/44Sc generator, explored the pharmacokinetic profiles of 44ScCl3, [44Sc]-citrate and [44Sc]-NODAGA (1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid) in naïve mice, and estimated the radiation burden of 44ScCl3 in humans. METHODS 44Ti/44Sc (101.2 MBq) in 6 M HCl solution was utilized to assemble a modular ZR resin containing generator. After assembly, 44Sc was eluted with 0.05 M HCl for further PET imaging and biodistribution studies in female Swiss Webster mice. Based on the biodistribution data, absorbed doses of 44/47ScCl3 in human adults were calculated for 18 organs and tissues using the IDAC-Dose software. RESULTS 44Ti in 6 M HCl was loaded onto the organic resin generator with a yield of 99.97%. After loading and initial stabilization, 44ScCl3 was eluted with 0.05 M HCl in typical yields of 82.9 ± 5.3% (N = 16), which was normalized to the estimated generator capacity. Estimated generator capacity was computed based on elution time interval and the total amount of 44Ti loaded on the generator. Run in forward and reverse directions, the 44Sc/44Ti ratio from a primary column was significantly improved from 1038 ± 440 to 3557 ± 680 (Bq/Bq) when a secondary, replaceable, ZR resin cartridge was employed at the flow outlet. In vivo imaging and ex vivo distribution studies of the reversible modular generator for 44ScCl3, [44Sc]-citrate and [44Sc]-NODAGA show that free 44Sc remained in the circulation significantly longer than the chelated 44Sc. The dose estimation of 44ScCl3 reveals that the radiation burden is 0.146 mSv/MBq for a 70 kg adult male and 0.179 mSv/MBq for a 57 kg adult female. Liver, spleen and heart wall will receive the highest absorbed dose: 0.524, 0.502, and 0.303 mGy/MBq, respectively, for the adult male. CONCLUSIONS A clinical-scale 44Ti/44Sc generator system with a modular design was developed to supply 44ScCl3 in 0.05 M HCl, which is suitable for further radiolabeling and in vivo use. Our data demonstrated that free 44ScCl3 remained in the circulation for extended periods, which resulted in approximately 10 times greater radiation burden than stably chelated 44Sc. Stable 44Sc/47Sc-complexation will be more favorable for in vivo use and for clinical utility.
Collapse
Affiliation(s)
- Nadia Benabdallah
- grid.4367.60000 0001 2355 7002Washington University School of Medicine, Mallinckrodt Institute of Radiology, 510 S. Kingshighway Boulevard, St. Louis, MO 63110 USA ,grid.4367.60000 0001 2355 7002Program in Quantitative Molecular Therapeutics, Washington University School of Medicine, St. Louis, MO 63110 USA
| | - Hanwen Zhang
- Washington University School of Medicine, Mallinckrodt Institute of Radiology, 510 S. Kingshighway Boulevard, St. Louis, MO, 63110, USA. .,Program in Quantitative Molecular Therapeutics, Washington University School of Medicine, St. Louis, MO, 63110, USA. .,Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO, 63110, USA.
| | - Ryan Unnerstall
- grid.4367.60000 0001 2355 7002Washington University School of Medicine, Mallinckrodt Institute of Radiology, 510 S. Kingshighway Boulevard, St. Louis, MO 63110 USA
| | - Amanda Fears
- grid.4367.60000 0001 2355 7002Washington University School of Medicine, Mallinckrodt Institute of Radiology, 510 S. Kingshighway Boulevard, St. Louis, MO 63110 USA ,grid.4367.60000 0001 2355 7002Program in Quantitative Molecular Therapeutics, Washington University School of Medicine, St. Louis, MO 63110 USA
| | - Lucy Summer
- grid.4367.60000 0001 2355 7002Washington University School of Medicine, Mallinckrodt Institute of Radiology, 510 S. Kingshighway Boulevard, St. Louis, MO 63110 USA
| | - Michael Fassbender
- grid.148313.c0000 0004 0428 3079Chemistry Division, Los Alamos National Laboratory, PO Box 1663, Los Alamos, NM 87545 USA
| | - Buck E. Rodgers
- grid.4367.60000 0001 2355 7002Washington University School of Medicine, Mallinckrodt Institute of Radiology, 510 S. Kingshighway Boulevard, St. Louis, MO 63110 USA ,grid.516080.a0000 0004 0373 6443Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO 63110 USA ,grid.4367.60000 0001 2355 7002Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO 63110 USA
| | - Diane Abou
- grid.4367.60000 0001 2355 7002Washington University School of Medicine, Mallinckrodt Institute of Radiology, 510 S. Kingshighway Boulevard, St. Louis, MO 63110 USA ,grid.516080.a0000 0004 0373 6443Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO 63110 USA ,grid.4367.60000 0001 2355 7002Mallinckrodt Cyclotron Facility, Washington University School of Medicine, St. Louis, MO 63110 USA
| | - Valery Radchenko
- grid.232474.40000 0001 0705 9791Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC V6T 2A3 Canada ,grid.17091.3e0000 0001 2288 9830Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, BC V6T 1Z1 Canada
| | - Daniel L. J. Thorek
- grid.4367.60000 0001 2355 7002Washington University School of Medicine, Mallinckrodt Institute of Radiology, 510 S. Kingshighway Boulevard, St. Louis, MO 63110 USA ,grid.4367.60000 0001 2355 7002Program in Quantitative Molecular Therapeutics, Washington University School of Medicine, St. Louis, MO 63110 USA ,grid.516080.a0000 0004 0373 6443Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO 63110 USA ,grid.4367.60000 0001 2355 7002Department of Biomedical Engineering, Washington University, St. Louis, MO 63110 USA
| |
Collapse
|
9
|
Qi J, Huang B. Positronium Lifetime Image Reconstruction for TOF PET. IEEE TRANSACTIONS ON MEDICAL IMAGING 2022; 41:2848-2855. [PMID: 35584079 PMCID: PMC9829407 DOI: 10.1109/tmi.2022.3174561] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Positron emission tomography is widely used in clinical and preclinical applications. Positronium lifetime carries information about the tissue microenvironment where positrons are emitted, but such information has not been captured because of two technical challenges. One challenge is the low sensitivity in detecting triple coincidence events. This problem has been mitigated by the recent developments of PET scanners with long (1-2 m) axial field of view. The other challenge is the low spatial resolution of the positronium lifetime images formed by existing methods that is determined by the time-of-flight (TOF) resolution (200-500 ps) of existing PET scanners. This paper solves the second challenge by developing a new image reconstruction method to generate high-resolution positronium lifetime images using existing TOF PET. Simulation studies demonstrate that the proposed method can reconstruct positronium lifetime images at much better spatial resolution than the limit set by the TOF resolution of the PET scanner. The proposed method opens up the possibility of performing positronium lifetime imaging using existing TOF PET scanners. The lifetime information can be used to understand the tissue microenvironment in vivo which could facilitate the study of disease mechanism and selection of proper treatments.
Collapse
|
10
|
Śmiłowicz D, Schlyer D, Boros E, Meimetis L. Evaluation of a Radio-IMmunoStimulant (RIMS) in a Syngeneic Model of Murine Prostate Cancer and ImmunoPET Analysis of T-cell Distribution. Mol Pharm 2022; 19:3217-3227. [PMID: 35895995 DOI: 10.1021/acs.molpharmaceut.2c00361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
An immunosuppressive tumor microenvironment and tumor heterogeneity have led to the resilience of metastatic castrate resistant prostate cancer (mCRPC) to current treatments. To address these challenges, we developed and evaluated a new drug paradigm, Radio-IMmunostimulant (RIMS), in a syngeneic model of murine prostate cancer. RIMS-1 was generated using a convergent synthesis employing solid phase peptide and solution chemistries. The prostate-specific membrane antigen (PSMA) inhibitory constant for natLu-RIMS-1 was determined, and radiolabeling with 177Lu generated 177Lu-RIMS-1. The TLR 7/8 agonist payload release from natLu-RIMS-1 was determined using a cathepsin B assay. The biodistribution of 177Lu-RIMS-1 was evaluated in a bilateral xenograft model in NCru nude mice bearing PSMA(+) (PC3-PiP) and PSMA(-) (PC3-Flu) tumors at 2, 24, and 72 h. The therapeutic effect of 177Lu-RIMS-1 was evaluated in C57BL/6J mice bearing RM1-PGLS (PSMA-positive, green fluorescent protein-positive, and luciferase-positive) tumors and compared to that of 177Lu-PSMA-617 at the same total administered radioactivity of 57 MBq and molar activity of 5.18 MBq/nmol. natLu-RIMS-1 and vehicle were evaluated as the controls. Immuno-positron emission tomography (PET) using 89Zr-DFO-anti-CD3 was used to visualize T-cell distribution during treatment. 177Lu-RIMS-1 was quantitatively radiolabeled at >99% radiochemical purity and maintained a high affinity toward PSMA (Ki = 3.77 ± 0.5 nM). Cathepsin B efficiently released the entire immunostimulant payload in 17.6 h. 177Lu-RIMS-1 displayed a sustained uptake in PSMA(+) tumor tissue up to 72 h (2.65 ± 1.03% ID/g) and was not statistically different (P = 0.1936) compared to 177Lu-PSMA-617 (3.65 ± 0.59% ID/g). All animals treated with 177Lu-RIMS-1 displayed tumor growth suppression and provided a median survival of 30 days (P = 0.0007) while 177Lu-PSMA-617 provided a median survival of 15 days, which was not statistically significant (P = 0.3548) compared to the vehicle group (14 days). ImmunoPET analysis revealed 2-fold more tumor infiltrating T-cells in 177Lu-RIMS-1-treated animals compared to 177Lu-PSMA-617-treated animals; 177Lu-RIMS-1 improves therapeutic outcomes in a syngeneic model of mouse prostate cancer and elicits greater T-cell infiltration to the tumor compared to 177Lu-PSMA-617. These results support further investigation of the RIMS paradigm as the first example of a single molecular entity combining radiotherapy and immunostimulation.
Collapse
Affiliation(s)
- Dariusz Śmiłowicz
- Department of Chemistry, Stony Brook University, Stony Brook, New York 11794, United States
| | - David Schlyer
- Department of Radiology, Stony Brook University, Stony Brook, New York 11794, United States.,Brookhaven National Laboratory, Upton, New York 11973, United States
| | - Eszter Boros
- Department of Chemistry, Stony Brook University, Stony Brook, New York 11794, United States
| | - Labros Meimetis
- Department of Radiology, Stony Brook University, Stony Brook, New York 11794, United States
| |
Collapse
|
11
|
Aldrich KE, Popov IA, Root HD, Batista ER, Greer SM, Kozimor SA, Lilley LM, Livshits MY, Mocko V, Janicke MT, Scott BL, Stein BW, Yang P. Synthesis, solid-state, solution, and theoretical characterization of an "in-cage" scandium-NOTA complex. Dalton Trans 2022; 51:9994-10005. [PMID: 35739082 DOI: 10.1039/d1dt03887g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Developing chelators that strongly and selectively bind rare-earth elements (Sc, Y, La, and lanthanides) represents a longstanding fundamental challenge in inorganic chemistry. Solving these challenges is becoming more important because of increasing use of rare-earth elements in numerous technologies, ranging from paramagnets to luminescent materials. Within this context, we interrogated the complexation chemistry of the scandium(III) (Sc3+) trication with the hexadentate 1,4,7-triazacyclononane-1,4,7-triacetic acid (H3NOTA) chelator. This H3NOTA chelator is often regarded as an underperformer for complexing Sc3+. A common assumption is that metalation does not fully encapsulate Sc3+ within the NOTA3- macrocycle, leaving Sc3+ on the periphery of the chelate and susceptible to demetalation. Herein, we developed a synthetic approach that contradicted those assumptions. We confirmed that our procedure forced Sc3+ into the NOTA3- binding pocket by using single crystal X-ray diffraction to determine the Na[Sc(NOTA)(OOCCH3)] structure. Density functional theory (DFT) and 45Sc nuclear magnetic resonance (NMR) spectroscopy showed Sc3+ encapsulation was retained when the crystals were dissolved. Solution-phase and DFT studies revealed that [Sc(NOTA)(OOCCH3)]1- could accommodate an additional H2O capping ligand. Thermodynamic properties associated with the Sc-OOCCH3 and Sc-H2O capping ligand interactions demonstrated that these capping ligands occupied critical roles in stabilizing the [Sc(NOTA)] chelation complex.
Collapse
Affiliation(s)
| | - Ivan A Popov
- Los Alamos National Laboratory, Los Alamos, NM, USA. .,Department of Chemistry, The University of Akron, Akron, Ohio 44325-3601, USA
| | | | | | | | | | | | | | | | | | - Brian L Scott
- Los Alamos National Laboratory, Los Alamos, NM, USA.
| | | | - Ping Yang
- Los Alamos National Laboratory, Los Alamos, NM, USA.
| |
Collapse
|
12
|
Hu Y, Chen D, Napoleon JV, Srinivasarao M, Singhal S, Savran CA, Low PS. Efficient capture of circulating tumor cells with low molecular weight folate receptor-specific ligands. Sci Rep 2022; 12:8555. [PMID: 35595733 PMCID: PMC9122947 DOI: 10.1038/s41598-022-12118-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Accepted: 04/29/2022] [Indexed: 11/09/2022] Open
Abstract
Retrieval of circulating tumor cells (CTC) has proven valuable for assessing a patient's cancer burden, evaluating response to therapy, and analyzing which drug might treat a cancer best. Although most isolation methods retrieve CTCs based on size, shape, or capture by tumor-specific antibodies, we explore here the use of small molecule tumor-specific ligands linked to magnetic beads for CTC capture. We have designed folic acid-biotin conjugates with different linkers for the capture of folate receptor (FR) + tumor cells spiked into whole blood, and application of the same technology to isolate FR + CTCs from the peripheral blood of both tumor-bearing mice and non-small cell lung patients. We demonstrate that folic acid linked via a rigid linker to a flexible PEG spacer that is in turn tethered to a magnetic bead enables optimal CTC retrieval, reaching nearly 100% capture when 100 cancer cells are spiked into 1 mL of aqueous buffer and ~ 90% capture when the same quantity of cells is diluted into whole blood. In a live animal model, the same methodology is shown to efficiently retrieve CTCs from tumor-bearing mice, yielding cancer cell counts that are proportional to total tumor burden. More importantly, the same method is shown to collect ~ 29 CTCs/8 mL peripheral blood from patients with non-small cell lung cancer. Since the ligand-presentation strategy optimized here should also prove useful in targeting other nanoparticles to other cells, the methods described below should have general applicability in the design of nanoparticles for cell-specific targeting.
Collapse
Affiliation(s)
- Yingwen Hu
- Department of Chemistry, Purdue Center for Cancer Research, Purdue Institute for Drug Discovery, Purdue University, 720 Clinic Drive, West Lafayette, IN, 47907, USA
| | - Danyang Chen
- Department of Chemistry, Purdue Center for Cancer Research, Purdue Institute for Drug Discovery, Purdue University, 720 Clinic Drive, West Lafayette, IN, 47907, USA
| | - John V Napoleon
- Department of Chemistry, Purdue Center for Cancer Research, Purdue Institute for Drug Discovery, Purdue University, 720 Clinic Drive, West Lafayette, IN, 47907, USA
| | - Madduri Srinivasarao
- Department of Chemistry, Purdue Center for Cancer Research, Purdue Institute for Drug Discovery, Purdue University, 720 Clinic Drive, West Lafayette, IN, 47907, USA
| | - Sunil Singhal
- Division of Thoracic Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA
| | - Cagri A Savran
- School of Mechanical Engineering, Birck Nanotechnology Center, Purdue Center for Cancer Research, Purdue University, 1205 W. State St., West Lafayette, IN, 47907, USA
| | - Philip S Low
- Department of Chemistry, Purdue Center for Cancer Research, Purdue Institute for Drug Discovery, Purdue University, 720 Clinic Drive, West Lafayette, IN, 47907, USA.
| |
Collapse
|
13
|
Design, synthesis, and preclinical evaluation of a novel bifunctional macrocyclic chelator for theranostics of cancers. Eur J Nucl Med Mol Imaging 2022; 49:2618-2633. [DOI: 10.1007/s00259-022-05750-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2021] [Accepted: 03/01/2022] [Indexed: 12/22/2022]
|
14
|
Whetter JN, Vaughn BA, Koller AJ, Boros E. An Unusual Pair: Facile Formation and In Vivo Validation of Robust Sc–
18
F Ternary Complexes for Molecular Imaging. Angew Chem Int Ed Engl 2022. [DOI: 10.1002/ange.202114203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Jennifer N. Whetter
- Department of Chemistry Stony Brook University 100 Nicolls Road, Stony Brook New York 11794 USA
| | - Brett A. Vaughn
- Department of Chemistry Stony Brook University 100 Nicolls Road, Stony Brook New York 11794 USA
| | - Angus J. Koller
- Department of Chemistry Stony Brook University 100 Nicolls Road, Stony Brook New York 11794 USA
| | - Eszter Boros
- Department of Chemistry Stony Brook University 100 Nicolls Road, Stony Brook New York 11794 USA
| |
Collapse
|
15
|
Miller C, Rousseau J, Ramogida CF, Celler A, Rahmim A, Uribe CF. Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs. Theranostics 2022; 12:232-259. [PMID: 34987643 PMCID: PMC8690938 DOI: 10.7150/thno.62851] [Citation(s) in RCA: 20] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Accepted: 10/18/2021] [Indexed: 12/15/2022] Open
Abstract
Theranostics is an emerging paradigm that combines imaging and therapy in order to personalize patient treatment. In nuclear medicine, this is achieved by using radiopharmaceuticals that target identical molecular targets for both imaging (using emitted gamma rays) and radiopharmaceutical therapy (using emitted beta, alpha or Auger-electron particles) for the treatment of various diseases, such as cancer. If the therapeutic radiopharmaceutical cannot be imaged quantitatively, a “theranostic pair” imaging surrogate can be used to predict the absorbed radiation doses from the therapeutic radiopharmaceutical. However, theranostic dosimetry assumes that the pharmacokinetics and biodistributions of both radiopharmaceuticals in the pair are identical or very similar, an assumption that still requires further validation for many theranostic pairs. In this review, we consider both same-element and different-element theranostic pairs and attempt to determine if factors exist which may cause inaccurate dose extrapolations in theranostic dosimetry, either intrinsic (e.g. chemical differences) or extrinsic (e.g. injecting different amounts of each radiopharmaceutical) to the radiopharmaceuticals. We discuss the basis behind theranostic dosimetry and present common theranostic pairs and their therapeutic applications in oncology. We investigate general factors that could create alterations in the behavior of the radiopharmaceuticals or the quantitative accuracy of imaging them. Finally, we attempt to determine if there is evidence showing some specific pairs as suitable for theranostic dosimetry. We show that there are a variety of intrinsic and extrinsic factors which can significantly alter the behavior among pairs of radiopharmaceuticals, even if they belong to the same chemical element. More research is needed to determine the impact of these factors on theranostic dosimetry estimates and on patient outcomes, and how to correctly account for them.
Collapse
|
16
|
Whetter JN, Vaughn BA, Koller AJ, Boros E. An Unusual Pair: Facile Formation and In Vivo Validation of Robust Sc- 18 F Ternary Complexes for Molecular Imaging. Angew Chem Int Ed Engl 2021; 61:e202114203. [PMID: 34889014 DOI: 10.1002/anie.202114203] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2021] [Indexed: 12/11/2022]
Abstract
Fluorine-18 remains the most widely clinically utilized radionuclide globally for positron emission tomography (PET). The emergence of therapeutic isotopes for the management of disease has produced a pronounced interest in matched, theranostic isotope pairs that can be employed in tandem for the diagnosis and stratification of patients for subsequent radiotherapy. 18 F, however, does not have a suitable therapeutic isotopologue. Here, we demonstrate that the formation of [18 F][Sc-F] ternary complexes is feasible under mild, aqueous conditions, producing chemically robust radiopharmaceuticals in high radiochemical yield and specific activity. A corresponding in vivo study with a cancer-targeting [18 F][Sc-F] tracer indicates excellent in vivo stability and produces exquisite PET image quality, rendering the 18 F/47 Sc isotope pair an unusual, yet chemically matched theranostic pair with excellent potential for clinical translation.
Collapse
Affiliation(s)
- Jennifer N Whetter
- Department of Chemistry, Stony Brook University, 100 Nicolls Road, Stony Brook, New York, 11794, USA
| | - Brett A Vaughn
- Department of Chemistry, Stony Brook University, 100 Nicolls Road, Stony Brook, New York, 11794, USA
| | - Angus J Koller
- Department of Chemistry, Stony Brook University, 100 Nicolls Road, Stony Brook, New York, 11794, USA
| | - Eszter Boros
- Department of Chemistry, Stony Brook University, 100 Nicolls Road, Stony Brook, New York, 11794, USA
| |
Collapse
|
17
|
Vaughn BA, Loveless CS, Cingoranelli SJ, Schlyer D, Lapi SE, Boros E. Evaluation of 177Lu and 47Sc Picaga-Linked, Prostate-Specific Membrane Antigen-Targeting Constructs for Their Radiotherapeutic Efficacy and Dosimetry. Mol Pharm 2021; 18:4511-4519. [PMID: 34714082 DOI: 10.1021/acs.molpharmaceut.1c00711] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Lu-177-based, targeted radiotherapeutics/endoradiotherapies are an emerging clinical tool for the management of various cancers. The chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) remains the workhorse for such applications but can limit apparent molar activity or efficient charge modulation, which can impact target binding and, as a consequence, target efficacy. Previously, our lab had developed the small, rare earth selective bifunctional chelator, picaga, as an efficient bifunctional chelator for scandium and lutetium isotopes. Here, we assess the performance of these constructs for therapy in prostate-specific membrane antigen (PSMA)-expressing tumor xenografts. To assess the viability of picaga conjugates in conjunction with long in vivo circulation, a picaga conjugate functionalized with a serum albumin binding moiety, 177Lu-picaga-Alb53-PSMA, was also synthesized. A directly comparative, low, single 3.7 MBq dose treatment study with Lu-PSMA-617 was conducted. Treatment with 177Lu-picaga-Alb53-PSMA resulted in tumor regression and lengthened median survival (54 days) when compared with the vehicle (16 days), 47Sc-picaga-DUPA-, 177Lu-picaga-DUPA-, and 177Lu-PSMA-617-treated cohorts (21, 23, and 21 days, respectively).
Collapse
Affiliation(s)
- Brett A Vaughn
- Department of Chemistry, Stony Brook University, 100 Nicolls Road, Stony Brook, New York 11794, United States
| | - C Shaun Loveless
- Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States
| | - Shelbie J Cingoranelli
- Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States
| | - David Schlyer
- Brookhaven National Laboratory, Upton, New York 11973, United States.,Department of Biomedical Engineering, Stony Brook University, Stony Brook, New York 11794, United States
| | - Suzanne E Lapi
- Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States
| | - Eszter Boros
- Department of Chemistry, Stony Brook University, 100 Nicolls Road, Stony Brook, New York 11794, United States
| |
Collapse
|
18
|
Sneddon D, Cornelissen B. Emerging chelators for nuclear imaging. Curr Opin Chem Biol 2021; 63:152-162. [PMID: 34051509 DOI: 10.1016/j.cbpa.2021.03.001] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2020] [Revised: 02/28/2021] [Accepted: 03/09/2021] [Indexed: 11/25/2022]
Abstract
Chelators are necessary in nuclear medicine imaging to direct an inorganic radionuclide, a radiometal, to a desired target; unfortunately, there is no 'one-size-fits-all' chelator. As the toolbox of radiometals is expanding, new chelators are required to prevent off-target side effects. 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) is the current gold standard chelator for several radiometals, but typically, chelation requires harsh conditions, making it unsuitable to label biological vectors. The ideal chelator would allow labelling under mild conditions (near-neutral pH and low temperatures [∼37 °C]) and be both thermodynamically and kinetically stable. Over the past 2-3 years, several exciting chelators have been developed that have superior properties to make them worth investigating for future clinical applications.
Collapse
Affiliation(s)
- Deborah Sneddon
- MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, OX3 7LE, United Kingdom.
| | - Bart Cornelissen
- MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, OX3 7LE, United Kingdom
| |
Collapse
|
19
|
Hu A, Aluicio-Sarduy E, Brown V, MacMillan SN, Becker KV, Barnhart TE, Radchenko V, Ramogida CF, Engle JW, Wilson JJ. Py-Macrodipa: A Janus Chelator Capable of Binding Medicinally Relevant Rare-Earth Radiometals of Disparate Sizes. J Am Chem Soc 2021; 143:10429-10440. [PMID: 34190542 DOI: 10.1021/jacs.1c05339] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Nuclear medicine leverages different types of radiometals for disease diagnosis and treatment, but these applications usually require them to be stably chelated. Given the often-disparate chemical properties of these radionuclides, it is challenging to find a single chelator that binds all of them effectively. Toward addressing this problem, we recently reported a macrocyclic chelator macrodipa with an unprecedented "dual-size-selectivity" pattern for lanthanide (Ln3+) ions, characterized by its high affinity for both the large and the small Ln3+ ( J. Am. Chem. Soc, 2020, 142, 13500). Here, we describe a second-generation "macrodipa-type" ligand, py-macrodipa. Its coordination chemistry with Ln3+ was thoroughly investigated experimentally and computationally. These studies reveal that the Ln3+-py-macrodipa complexes exhibit enhanced thermodynamic and kinetic stabilities compared to Ln3+-macrodipa, while retaining the unusual dual-size selectivity. Nuclear medicine applications of py-macrodipa for chelating radiometals with disparate chemical properties were assessed using the therapeutic 135La3+ and diagnostic 44Sc3+ radiometals representing the two size extremes within the rare-earth series. Radiolabeling and stability studies demonstrate that the rapidly formed complexes of these radionuclides with py-macrodipa are highly stable in human serum. Thus, in contrast to gold standard chelators like DOTA and macropa, py-macrodipa can be harnessed for the simultaneous, efficient binding of radiometals with disparate ionic radii like La3+ and Sc3+, signifying a substantial achievement in nuclear medicine. This concept could enable the facile incorporation of a breadth of medicinally relevant radiometals into chemically identical radiopharmaceutical agents. The fundamental coordination chemistry learned from py-macrodipa provides valuable insight for future chelator development.
Collapse
Affiliation(s)
- Aohan Hu
- Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York 14853, United States
| | - Eduardo Aluicio-Sarduy
- Department of Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States
| | - Victoria Brown
- Department of Chemistry, Simon Fraser University, Burnaby, British Columbia V5A 1S6, Canada
| | - Samantha N MacMillan
- Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York 14853, United States
| | - Kaelyn V Becker
- Department of Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States.,Department of Radiology, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States
| | - Todd E Barnhart
- Department of Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States
| | - Valery Radchenko
- Life Sciences Division, TRIUMF, Vancouver, British Columbia V6T 2A3, Canada.,Department of Chemistry, University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
| | - Caterina F Ramogida
- Department of Chemistry, Simon Fraser University, Burnaby, British Columbia V5A 1S6, Canada.,Life Sciences Division, TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - Jonathan W Engle
- Department of Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States.,Department of Radiology, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States
| | - Justin J Wilson
- Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York 14853, United States
| |
Collapse
|
20
|
Mikolajczak R, Huclier-Markai S, Alliot C, Haddad F, Szikra D, Forgacs V, Garnuszek P. Production of scandium radionuclides for theranostic applications: towards standardization of quality requirements. EJNMMI Radiopharm Chem 2021; 6:19. [PMID: 34036449 PMCID: PMC8149571 DOI: 10.1186/s41181-021-00131-2] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2021] [Accepted: 03/26/2021] [Indexed: 01/23/2023] Open
Abstract
In the frame of "precision medicine", the scandium radionuclides have recently received considerable interest, providing personalised adjustment of radiation characteristics to optimize the efficiency of medical care or therapeutic benefit for particular groups of patients. Radionuclides of scandium, namely scandium-43 and scandium-44 (43/44Sc) as positron emitters and scandium-47 (47Sc), beta-radiation emitter, seem to fit ideally into the concept of theranostic pair. This paper aims to review the work on scandium isotopes production, coordination chemistry, radiolabeling, preclinical studies and the very first clinical studies. Finally, standardized procedures for scandium-based radiopharmaceuticals have been proposed as a basis to pave the way for elaboration of the Ph.Eur. monographs for perspective scandium radionuclides.
Collapse
Affiliation(s)
- R Mikolajczak
- Radioisotope Centre POLATOM, National Centre for Nuclear Research, Andrzej Soltan 7, 05-400, Otwock, Poland
| | - S Huclier-Markai
- Laboratoire Subatech, UMR 6457, IMT Nantes Atlantique /CNRS-IN2P3 / Université de Nantes, 4 Rue A. Kastler, BP 20722, 44307, Nantes Cedex 3, France.
- ARRONAX GIP, 1 rue Aronnax, 44817, Nantes Cedex, France.
| | - C Alliot
- ARRONAX GIP, 1 rue Aronnax, 44817, Nantes Cedex, France
- CRCINA, Inserm / CNRS / Université de Nantes, 8 quai Moncousu, 44007, Nantes Cedex 1, France
| | - F Haddad
- Laboratoire Subatech, UMR 6457, IMT Nantes Atlantique /CNRS-IN2P3 / Université de Nantes, 4 Rue A. Kastler, BP 20722, 44307, Nantes Cedex 3, France
- ARRONAX GIP, 1 rue Aronnax, 44817, Nantes Cedex, France
| | - D Szikra
- Faculty of Medicine, Department of Medical Imaging, Division of Nuclear Medicine and Translational Imaging, University of Debrecen, Nagyerdei krt. 98, Debrecen, 4032, Hungary
- Scanomed Ltd., Nagyerdei krt. 98, Debrecen, 4032, Hungary
| | - V Forgacs
- Faculty of Medicine, Department of Medical Imaging, Division of Nuclear Medicine and Translational Imaging, University of Debrecen, Nagyerdei krt. 98, Debrecen, 4032, Hungary
| | - P Garnuszek
- Radioisotope Centre POLATOM, National Centre for Nuclear Research, Andrzej Soltan 7, 05-400, Otwock, Poland
| |
Collapse
|
21
|
Chomet M, van Dongen GAMS, Vugts DJ. State of the Art in Radiolabeling of Antibodies with Common and Uncommon Radiometals for Preclinical and Clinical Immuno-PET. Bioconjug Chem 2021; 32:1315-1330. [PMID: 33974403 PMCID: PMC8299458 DOI: 10.1021/acs.bioconjchem.1c00136] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
![]()
Inert
and stable radiolabeling of monoclonal antibodies (mAb),
antibody fragments, or antibody mimetics with radiometals is a prerequisite
for immuno-PET. While radiolabeling is preferably fast, mild, efficient,
and reproducible, especially when applied for human use in a current
Good Manufacturing Practice compliant way, it is crucial that the
obtained radioimmunoconjugate is stable and shows preserved immunoreactivity
and in vivo behavior. Radiometals and chelators have
extensively been evaluated to come to the most ideal radiometal–chelator
pair for each type of antibody derivative. Although PET imaging of
antibodies is a relatively recent tool, applications with 89Zr, 64Cu, and 68Ga have greatly increased in
recent years, especially in the clinical setting, while other less
common radionuclides such as 52Mn, 86Y, 66Ga, and 44Sc, but also 18F as in [18F]AlF are emerging promising candidates for the radiolabeling
of antibodies. This review presents a state of the art overview of
the practical aspects of radiolabeling of antibodies, ranging from
fast kinetic affibodies and nanobodies to slow kinetic intact mAbs.
Herein, we focus on the most common approach which consists of first
modification of the antibody with a chelator, and after eventual storage
of the premodified molecule, radiolabeling as a second step. Other
approaches are possible but have been excluded from this review. The
review includes recent and representative examples from the literature
highlighting which radiometal–chelator–antibody combinations
are the most successful for in vivo application.
Collapse
Affiliation(s)
- Marion Chomet
- Amsterdam UMC, Vrije Universiteit Amsterdam, Radiology & Nuclear Medicine, Cancer Center Amsterdam, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands
| | - Guus A M S van Dongen
- Amsterdam UMC, Vrije Universiteit Amsterdam, Radiology & Nuclear Medicine, Cancer Center Amsterdam, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands
| | - Danielle J Vugts
- Amsterdam UMC, Vrije Universiteit Amsterdam, Radiology & Nuclear Medicine, Cancer Center Amsterdam, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands
| |
Collapse
|
22
|
Herrero Álvarez N, Bauer D, Hernández-Gil J, Lewis JS. Recent Advances in Radiometals for Combined Imaging and Therapy in Cancer. ChemMedChem 2021; 16:2909-2941. [PMID: 33792195 DOI: 10.1002/cmdc.202100135] [Citation(s) in RCA: 30] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2021] [Indexed: 12/14/2022]
Abstract
Nuclear medicine is defined as the use of radionuclides for diagnostic and therapeutic applications. The imaging modalities positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are based on γ-emissions of specific energies. The therapeutic technologies are based on β- -particle-, α-particle-, and Auger electron emitters. In oncology, PET and SPECT are used to detect cancer lesions, to determine dosimetry, and to monitor therapy effectiveness. In contrast, radiotherapy is designed to irreparably damage tumor cells in order to eradicate or control the disease's progression. Radiometals are being explored for the development of diagnostic and therapeutic radiopharmaceuticals. Strategies that combine both modalities (diagnostic and therapeutic), referred to as theranostics, are promising candidates for clinical applications. This review provides an overview of the basic concepts behind therapeutic and diagnostic radiopharmaceuticals and their significance in contemporary oncology. Select radiometals that significantly impact current and upcoming cancer treatment strategies are grouped as clinically suitable theranostics pairs. The most important physical and chemical properties are discussed. Standard production methods and current radionuclide availability are provided to indicate whether a cost-efficient use in a clinical routine is feasible. Recent preclinical and clinical developments and outline perspectives for the radiometals are highlighted in each section.
Collapse
Affiliation(s)
- Natalia Herrero Álvarez
- Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - David Bauer
- Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Javier Hernández-Gil
- Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.,Biomedical MRI/MoSAIC, Department of Imaging and Pathology, Katholieke Universiteit, Herestraat 49, 3000, Leuven, Belgium
| | - Jason S Lewis
- Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.,Department of Radiology, Weill Cornell Medical College, 1300 York Avenue, New York, NY, 10065, USA.,Department of Pharmacology, Weill-Cornell Medical College, New York, NY, 10065, USA
| |
Collapse
|
23
|
Vaughn BA, Koller AJ, Boros E. Aqueous chemistry of the smallest rare earth: Comprehensive characterization of radioactive and non-radioactive scandium complexes for biological applications. Methods Enzymol 2021; 651:343-371. [PMID: 33888209 DOI: 10.1016/bs.mie.2021.01.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The aqueous chemistry of scandium(III) is of emerging interest for biological applications, specifically in nuclear medicine, as radioactive isotopes of scandium are becoming more readily accessible. In contrast to other rare earths, Sc3+ has no d or f electrons, limiting characterization of corresponding coordination complexes to spectroscopic techniques that do not rely on the characteristic electronic transitions of f-elements or transition metal ions. Herein, we provide a comprehensive overview on characterization techniques suitable to elucidate the solution behavior of small and macromolecular complexes of the smallest rare earth.
Collapse
Affiliation(s)
- Brett A Vaughn
- Department of Chemistry, Stony Brook University, Stony Brook, NY, United States
| | - Angus J Koller
- Department of Chemistry, Stony Brook University, Stony Brook, NY, United States
| | - Eszter Boros
- Department of Chemistry, Stony Brook University, Stony Brook, NY, United States.
| |
Collapse
|
24
|
Design and synthesis of a new conjugate of a tris(3-hydroxy-4-pyridinone) chelator (KC18) for potential use as gallium-68-labeled prostate-specific membrane antigen (PSMA) radiopharmaceutical. RESULTS IN CHEMISTRY 2021. [DOI: 10.1016/j.rechem.2021.100240] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
|
25
|
Vaughn BA, Koller AJ, Chen Z, Ahn SH, Loveless CS, Cingoranelli SJ, Yang Y, Cirri A, Johnson CJ, Lapi SE, Chapman KW, Boros E. Homologous Structural, Chemical, and Biological Behavior of Sc and Lu Complexes of the Picaga Bifunctional Chelator: Toward Development of Matched Theranostic Pairs for Radiopharmaceutical Applications. Bioconjug Chem 2020; 32:1232-1241. [PMID: 33284001 DOI: 10.1021/acs.bioconjchem.0c00574] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The radioactive isotopes scandium-44/47 and lutetium-177 are gaining relevance for radioimaging and radiotherapy, resulting in a surge of studies on their coordination chemistry and subsequent applications. Although the trivalent ions of these elements are considered close homologues, dissimilar chemical behavior is observed when they are complexed by large ligand architectures due to discrepancies between Lu(III) and Sc(III) ions with respect to size, chemical hardness, and Lewis acidity. Here, we demonstrate that Lu and Sc complexes of 1,4-bis(methoxycarbonyl)-7-[(6-carboxypyridin-2-yl)methyl]-1,4,7-triazacyclononane (H3mpatcn) and its corresponding bioconjugate picaga-DUPA can be employed to promote analogous structural features and, subsequently, biological properties for coordination complexes of these ions. The close homology was evidenced using potentiometric methods, computational modeling, variable temperature mass spectrometry, and pair distribution function analysis of X-ray scattering data. Radiochemical labeling, in vitro stability, and biodistribution studies with Sc-47 and Lu-177 indicate that the 7-coordinate ligand environment of the bifunctional picaga ligand is compatible with biological applications and the future investigation of β-emitting, picaga-chelated Sc and Lu isotopes for radiotherapy.
Collapse
Affiliation(s)
- Brett A Vaughn
- Department of Chemistry, Stony Brook University, 100 Nicolls Road, Stony Brook, New York 11794, United States
| | - Angus J Koller
- Department of Chemistry, Stony Brook University, 100 Nicolls Road, Stony Brook, New York 11794, United States
| | - Zhihengyu Chen
- Department of Chemistry, Stony Brook University, 100 Nicolls Road, Stony Brook, New York 11794, United States
| | - Shin Hye Ahn
- Department of Chemistry, Stony Brook University, 100 Nicolls Road, Stony Brook, New York 11794, United States
| | - C Shaun Loveless
- Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States
| | - Shelbie J Cingoranelli
- Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States
| | - Yi Yang
- Department of Chemistry, Stony Brook University, 100 Nicolls Road, Stony Brook, New York 11794, United States
| | - Anthony Cirri
- Department of Chemistry, Stony Brook University, 100 Nicolls Road, Stony Brook, New York 11794, United States
| | - Christopher J Johnson
- Department of Chemistry, Stony Brook University, 100 Nicolls Road, Stony Brook, New York 11794, United States
| | - Suzanne E Lapi
- Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States
| | - Karena W Chapman
- Department of Chemistry, Stony Brook University, 100 Nicolls Road, Stony Brook, New York 11794, United States
| | - Eszter Boros
- Department of Chemistry, Stony Brook University, 100 Nicolls Road, Stony Brook, New York 11794, United States
| |
Collapse
|
26
|
Vaughn BA, Brown AM, Ahn SH, Robinson JR, Boros E. Is Less More? Influence of the Coordination Geometry of Copper(II) Picolinate Chelate Complexes on Metabolic Stability. Inorg Chem 2020; 59:16095-16108. [DOI: 10.1021/acs.inorgchem.0c02314] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Brett A. Vaughn
- Department of Chemistry, Stony Brook University, 100 Nicolls Road, Stony Brook, New York 11794, United States
| | - Alexander M. Brown
- Department of Chemistry, Brown University, Providence, Rhode Island 02912, United States
| | - Shin Hye Ahn
- Department of Chemistry, Stony Brook University, 100 Nicolls Road, Stony Brook, New York 11794, United States
| | - Jerome R. Robinson
- Department of Chemistry, Brown University, Providence, Rhode Island 02912, United States
| | - Eszter Boros
- Department of Chemistry, Stony Brook University, 100 Nicolls Road, Stony Brook, New York 11794, United States
| |
Collapse
|
27
|
Mattocks JA, Cotruvo JA. Biological, biomolecular, and bio-inspired strategies for detection, extraction, and separations of lanthanides and actinides. Chem Soc Rev 2020; 49:8315-8334. [PMID: 33057507 DOI: 10.1039/d0cs00653j] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Lanthanides and actinides are elements of ever-increasing technological importance in the modern world. However, the similar chemical and physical properties within these groups make purification of individual elements a challenge. Current industrial standards for the extraction, separation, and purification of these metals from natural sources, recycled materials, and industrial waste are inefficient, relying upon harsh conditions, repetitive steps, and ligands with only modest selectivity. Biological, biomolecular, and bio-inspired strategies towards improving these separations and making them more environmentally sustainable have been researched for many years; however, these methods often have insufficient selectivity for practical application. Recent developments in the understanding of how lanthanides are selectively acquired and used by certain bacteria offer the opportunity for a newer, more efficient take on these designs, as well as the possibility for fundamentally new designs and strategies. Herein, we review current cell-based and biomolecular (primarily small-molecule and protein-based) methods for detection, extraction, and separations of f-block elements. We discuss how the increasing knowledge regarding the selective recognition, uptake, trafficking, and storage of these elements in biological systems has informed and will continue to promote development of novel approaches to achieve these ends.
Collapse
Affiliation(s)
- Joseph A Mattocks
- Department of Chemistry, The Pennsylvania State University, University Park, PA 16802, USA.
| | | |
Collapse
|
28
|
Developing scandium and yttrium coordination chemistry to advance theranostic radiopharmaceuticals. Commun Chem 2020; 3:61. [PMID: 36703424 PMCID: PMC9814396 DOI: 10.1038/s42004-020-0307-0] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2020] [Accepted: 04/22/2020] [Indexed: 01/29/2023] Open
Abstract
The octadentate siderophore analog 3,4,3-LI(1,2-HOPO), denoted 343-HOPO hereafter, is known to have high affinity for both trivalent and tetravalent lanthanide and actinide cations. Here we extend its coordination chemistry to the rare-earth cations Sc3+ and Y3+ and characterize fundamental metal-chelator binding interactions in solution via UV-Vis spectrophotometry, nuclear magnetic resonance spectroscopy, and spectrofluorimetric metal-competition titrations, as well as in the solid-state via single crystal X-ray diffraction. Sc3+ and Y3+ binding with 343-HOPO is found to be robust, with both high thermodynamic stability and fast room temperature radiolabeling, indicating that 343-HOPO is likely a promising chelator for in vivo applications with both metals. As a proof of concept, we prepared a 86Y-343-HOPO complex for in vivo PET imaging, and the results presented herein highlight the potential of 343-HOPO chelated trivalent metal cations for therapeutic and theranostic applications.
Collapse
|
29
|
Choudhary N, Guadalupe Jaraquemada-Peláez MD, Zarschler K, Wang X, Radchenko V, Kubeil M, Stephan H, Orvig C. Chelation in One Fell Swoop: Optimizing Ligands for Smaller Radiometal Ions. Inorg Chem 2020; 59:5728-5741. [DOI: 10.1021/acs.inorgchem.0c00509] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Affiliation(s)
- Neha Choudhary
- Medicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, British Columbia V6T 1Z1, Canada
- Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
| | - Marı́a de Guadalupe Jaraquemada-Peláez
- Medicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, British Columbia V6T 1Z1, Canada
| | - Kristof Zarschler
- Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
| | - Xiaozhu Wang
- Medicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, British Columbia V6T 1Z1, Canada
| | - Valery Radchenko
- Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
- Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, British Columbia V6T 1Z1, Canada
| | - Manja Kubeil
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstraße 400, D-01328 Dresden, Germany
| | - Holger Stephan
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstraße 400, D-01328 Dresden, Germany
| | - Chris Orvig
- Medicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, British Columbia V6T 1Z1, Canada
| |
Collapse
|